Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer. Yuan F, Li X, Hong C, Huang X, et al. J Biochem Mol Toxicol 2025;39:e70621.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yuan F, Li X, Hong C, Huang X, et al. Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer. J Biochem Mol Toxicol 2025;39:e70621.
PMID: 41276784